Artiva Biotherapeutics Reports Favorable Safety Profile for AlloNK Cell Therapy in 32 Autoimmune Disease Patients
核心洞察
Artiva Biotherapeutics will present initial safety data from 32 autoimmune disease patients treated with AlloNK plus monoclonal antibody therapy, showing a favorable tolerability profile and feasibility for outpatient administration.
The company's translational data demonstrates uniform, deep B-cell (搜索) depletion across all treated patients using high-sensitivity assays with 10- to 50-fold higher sensitivity than typical methods.
AlloNK is an allogeneic, off-the-shelf NK cell therapy designed to enhance antibody-dependent cellular cytotoxicity for B-cell (搜索) depletion in autoimmune diseases (搜索) including rheumatoid arthritis (搜索) and Sjögren's disease (搜索).
Artiva Biotherapeutics announced it will present encouraging initial safety and translational data for its lead cell therapy candidate AlloNK in combination with anti-CD20 (搜索) monoclonal antibodies (搜索) for treating autoimmune diseases (搜索). The clinical-stage biotechnology company will host a virtual webcast on November 12, 2025, featuring data from 32 patients with autoimmune diseases who received the combination therapy.
Favorable Safety Profile Observed
The initial safety data highlights a favorable tolerability profile observed to date in the 32 patients treated with AlloNK plus monoclonal antibody therapy. The treatment regimen, which includes cyclophosphamide/fludarabine conditioning, demonstrated ease-of-use and feasibility for administration and patient management in outpatient rheumatology clinics.
This outpatient administration capability represents a significant practical advantage for both patients and healthcare providers, potentially improving access to advanced cell therapy treatments for autoimmune conditions.
Deep B-Cell Depletion Achieved
The translational data reveals uniform, consistent, deep B-cell (搜索) depletion across all patients treated with the AlloNK combination therapy. Using high-sensitivity B-cell depletion assays with 10- to 50-fold higher sensitivity than typical assays, researchers demonstrated that patients achieved the intended mechanism of action for AlloNK.
The company also observed B-cell (搜索) reconstitution patterns in treated patients, showing a consistent preponderance of naïve and transitional cells at reconstitution. This pattern aligns with observations from auto-CAR-T treatment, suggesting similar therapeutic mechanisms may be at work.
Addressing Unmet Medical Need
The webcast will also characterize the unmet need in refractory rheumatoid arthritis (搜索) that AlloNK plus monoclonal antibody therapy has the potential to address. This focus on refractory cases highlights the therapy's potential role in treating patients who have not responded to conventional treatments.
AlloNK Technology Platform
AlloNK (also known as AB-101) is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate. The therapy is designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies (搜索) to drive B-cell (搜索) depletion in autoimmune diseases (搜索).
The therapy is currently being evaluated in three ongoing clinical trials for B-cell (搜索) driven autoimmune diseases (搜索), including a company-sponsored basket trial covering rheumatoid arthritis (搜索) and Sjögren's disease (搜索), and an investigator-initiated basket trial in B-cell driven autoimmune diseases.
Company Background
Artiva Biotherapeutics, headquartered in San Diego, California, was founded in 2019 as a spin-out of GC Cell (搜索), formerly GC Lab Cell Corporation, a leading healthcare company in South Korea. The strategic partnership grants Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell's NK cell manufacturing technology and programs.
Beyond autoimmune diseases (搜索), Artiva's pipeline includes CAR-NK candidates targeting both solid and hematologic cancers, positioning the company to address multiple therapeutic areas with its cell therapy platform.